FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394522> ?p ?o ?g. }

• W4308394522 abstract "<h3>Background</h3> The use of probiotic supplementation by cancer patients is increasing, including amongst those undergoing immune checkpoint inhibitor (ICI) therapy. While probiotic supplementation has been identified as an important factor influencing cancer patient responses to ICI therapy in melanoma, the underlying mechanisms of how gut probiotics shape systemic tumor immunity and thereby modulate ICI therapy efficacy remain poorly understood. <h3>Methods</h3> We used a preclinical melanoma model to identify various probiotic bacteria capable of suppressing tumor growth, and identified the mechanism by which the host-microbial crosstalk enables the most potent tumor-suppressing strain, <i>Lactobacillus reuteri</i>, to bolster a strong spontaneous antitumor immunity and increase anti-PD-L1 therapy efficacy. We interrogated the clinical relevance of our findings in a cohort of advanced melanoma patients that either responded or failed to respond to ICI therapy. <h3>Results</h3> Probiotic bacterium, <i>L. reuteri,</i> induces antitumor immunity and promotes ICI therapy in B16 preclinical melanoma via inducing interferon-gamma production by CD8 T cells.<i> L. reuteri</i> translocates to, colonizes and persists within melanoma tumors, and this intra-tumoral localization of L.reuteri is both necessary and sufficient to mediate antitumor effects in melanoma. <i>L. reuteri</i>-mediated tumor suppression occurs in a tumor- and <i>L. reuteri</i>-antigen independent fashion. The mechanism by which <i>L. reuteri</i> induces this antitumor response is via catabolization of a dietary tryptophan catabolite, indole-3-aldehyde (I3A). I3A is required and sufficient to promote antitumor immunity and facilitate ICI therapy efficacy, and it mediates antitumor immunity via activation of aryl hydrocarbon receptor (AhR) within CD8 T cells. The translational relevancy of I3A’s impact on clinical melanoma is supported by our evidence for a role of I3A in promoting anti-PD-1 immunotherapy efficacy and survival in advanced melanoma patients. <h3>Conclusions</h3> We show that probiotic bacterium <i>L. reuteri</i> can translocate to gut-distal melanoma tumors and reveal that its presence within the tumor is required to promote antitumor Tc1 cell immunity and facilitate ICI therapy in preclincial melanoma. Collectively, our findings elucidate a critical microbial-host crosstalk between the microbial released AhR agonist I3A and CD8 T cells within the tumor microenvironment that potently enhances spontaneous antitumor immunity and facilitates ICI therapy efficacy in preclinical melanoma. <h3>Ethics Approval</h3> Animal care and experimentation were conducted in accordance with NIH guidelines and approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. Approval to treat patients was obtained from the University of Pittsburgh’s Hillman Cancer Center (HCC) Institutional Review Board (No. PRO14030075), and authors attest that signed informed consent was obtained from all patients involved in the study. <h3>Consent</h3> N/A- no sensitive or identifiable information is included in this study." @default.
• W4308394522 created "2022-11-11" @default.
• W4308394522 creator A5001000053 @default.
• W4308394522 creator A5001219422 @default.
• W4308394522 creator A5016771679 @default.
• W4308394522 creator A5017077642 @default.
• W4308394522 creator A5017083341 @default.
• W4308394522 creator A5022984906 @default.
• W4308394522 creator A5024939227 @default.
• W4308394522 creator A5025286759 @default.
• W4308394522 creator A5030169825 @default.
• W4308394522 creator A5034920672 @default.
• W4308394522 creator A5048707762 @default.
• W4308394522 creator A5062160087 @default.
• W4308394522 creator A5065305751 @default.
• W4308394522 creator A5068016446 @default.
• W4308394522 creator A5071151211 @default.
• W4308394522 date "2022-11-01" @default.
• W4308394522 modified "2023-10-16" @default.
• W4308394522 title "1310 Dietary tryptophan catabolite released by intratumoral<i>Lactobacillus reuteri</i>facilitates anti-PD-L1 therapy" @default.
• W4308394522 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1310" @default.
• W4308394522 hasPublicationYear "2022" @default.
• W4308394522 type Work @default.
• W4308394522 citedByCount "0" @default.
• W4308394522 crossrefType "proceedings-article" @default.
• W4308394522 hasAuthorship W4308394522A5001000053 @default.
• W4308394522 hasAuthorship W4308394522A5001219422 @default.
• W4308394522 hasAuthorship W4308394522A5016771679 @default.
• W4308394522 hasAuthorship W4308394522A5017077642 @default.
• W4308394522 hasAuthorship W4308394522A5017083341 @default.
• W4308394522 hasAuthorship W4308394522A5022984906 @default.
• W4308394522 hasAuthorship W4308394522A5024939227 @default.
• W4308394522 hasAuthorship W4308394522A5025286759 @default.
• W4308394522 hasAuthorship W4308394522A5030169825 @default.
• W4308394522 hasAuthorship W4308394522A5034920672 @default.
• W4308394522 hasAuthorship W4308394522A5048707762 @default.
• W4308394522 hasAuthorship W4308394522A5062160087 @default.
• W4308394522 hasAuthorship W4308394522A5065305751 @default.
• W4308394522 hasAuthorship W4308394522A5068016446 @default.
• W4308394522 hasAuthorship W4308394522A5071151211 @default.
• W4308394522 hasBestOaLocation W43083945221 @default.
• W4308394522 hasConcept C121608353 @default.
• W4308394522 hasConcept C126322002 @default.
• W4308394522 hasConcept C203014093 @default.
• W4308394522 hasConcept C2775898472 @default.
• W4308394522 hasConcept C2776999253 @default.
• W4308394522 hasConcept C2777658100 @default.
• W4308394522 hasConcept C2777701055 @default.
• W4308394522 hasConcept C2779341262 @default.
• W4308394522 hasConcept C2780255968 @default.
• W4308394522 hasConcept C502942594 @default.
• W4308394522 hasConcept C523546767 @default.
• W4308394522 hasConcept C54355233 @default.
• W4308394522 hasConcept C71924100 @default.
• W4308394522 hasConcept C86803240 @default.
• W4308394522 hasConcept C8891405 @default.
• W4308394522 hasConceptScore W4308394522C121608353 @default.
• W4308394522 hasConceptScore W4308394522C126322002 @default.
• W4308394522 hasConceptScore W4308394522C203014093 @default.
• W4308394522 hasConceptScore W4308394522C2775898472 @default.
• W4308394522 hasConceptScore W4308394522C2776999253 @default.
• W4308394522 hasConceptScore W4308394522C2777658100 @default.
• W4308394522 hasConceptScore W4308394522C2777701055 @default.
• W4308394522 hasConceptScore W4308394522C2779341262 @default.
• W4308394522 hasConceptScore W4308394522C2780255968 @default.
• W4308394522 hasConceptScore W4308394522C502942594 @default.
• W4308394522 hasConceptScore W4308394522C523546767 @default.
• W4308394522 hasConceptScore W4308394522C54355233 @default.
• W4308394522 hasConceptScore W4308394522C71924100 @default.
• W4308394522 hasConceptScore W4308394522C86803240 @default.
• W4308394522 hasConceptScore W4308394522C8891405 @default.
• W4308394522 hasLocation W43083945221 @default.
• W4308394522 hasOpenAccess W4308394522 @default.
• W4308394522 hasPrimaryLocation W43083945221 @default.
• W4308394522 hasRelatedWork W1946934775 @default.
• W4308394522 hasRelatedWork W1996150995 @default.
• W4308394522 hasRelatedWork W2057948995 @default.
• W4308394522 hasRelatedWork W3017822181 @default.
• W4308394522 hasRelatedWork W3032210197 @default.
• W4308394522 hasRelatedWork W3158438576 @default.
• W4308394522 hasRelatedWork W3180780036 @default.
• W4308394522 hasRelatedWork W4291367166 @default.
• W4308394522 hasRelatedWork W4360983034 @default.
• W4308394522 hasRelatedWork W573847062 @default.
• W4308394522 isParatext "false" @default.
• W4308394522 isRetracted "false" @default.
• W4308394522 workType "article" @default.